Summary 415 million people live with diabetes worldwide, and an estimated 193 million
people have undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients …

Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-
lowering agent to manage type 2 diabetes. Its history is linked to Galega officinalis (also …

背景为期2 年的前瞻性MOSAIc (Multinational Observational Study assessing Insulin use:
understanding the challenges associated with progression of therapy, 评估胰岛素使用情况的 …

Metformin is one of the most popular oral glucose-lowering medications, widely considered
to be the optimal initial therapy for patients with type 2 diabetes mellitus. Interestingly, there …

Background Intensive glucose control is understood to prevent complications in adults with
type 2 diabetes. We aimed to more precisely estimate the effects of more intensive glucose …

Metformin is the most commonly prescribed drug for type 2 diabetes mellitus. In recent years,
in addition to glucose lowering, several studies have presented evidence suggesting some …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …

Exercise plays a central role in the management and treatment of common metabolic
diseases, but modern society presents many barriers to exercise. Over the past decade …

Background The best treatment option for patients with type 2 diabetes in whom treatment
with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to …

Aims To evaluate the effects of different sodium‐glucose co‐transporter 2 (SGLT2) inhibitors
on the risk of urinary tract infections (UTIs) and genital infections in patients with type 2 …